Navigation Links
TGV-Inhalonix Receives Orphan Drug Status for its Novel Antibiotic to Treat Resistant Infections in Cystic Fibrosis
Date:4/12/2016

NEW YORK, April 12, 2016 /PRNewswire/ -- TGV-Inhalonix, Inc., a New York-based pharmaceutical company, today announced that its new drug candidate for treating antibiotic-resistant bacterial lung infections in patients with cystic fibrosis has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA).

Logo - http://photos.prnewswire.com/prnh/20160412/354403LOGO

The FDA granted the special status for TGV-Inhalonix's antimicrobial agent Mul-1867.

"This is a breakthrough for our novel drug candidate, which has shown good results in early studies," said Dr. Victor Tetz, chief scientific advisor at TGV-Inhalonix.

"Previous studies have shown that Mul-1687 holds promise as a treatment for life-threatening pulmonary infections from Pseudomonas aeruginosa, Burkholderia cepacia, and other bacteria," said Dr. George Tetz, drug development advisor, at TGV-Inhalonix. "Our research revealed that Mul-1867 is more effective against antibiotic-resistant pathogens as compared with other drugs commonly used for the treatment of infections in cystic fibrosis patients."

The FDA grants Orphan Drug Designation status to products that treat rare diseases, providing incentives to sponsors developing drugs or biologics. The FDA defines rare diseases as those affecting fewer than 200,000 people in the United States at any given time.

The FDA granted the Orphan Drug Designation for Mul-1687 after reviewing multiple experimental research findings by TGV-Inhalonix. TGV-Inhalonix said its research indicates Mul-1867 holds promise for addressing unmet need for improved treatment of antibiotic-resistant pulmonary infections.

According to the Cystic Fibrosis Foundation, the median predicted survival age in persons with cystic fibrosis in the United States is 39.3 years. Chronic pulmonary infections lead to progressive decline in lung function and eventually respiratory failure in patients with cystic fibrosis.

TGV-Inhalonix also believes Mul-1867's unique mechanism offers a broad potential for the treatment of various bacterial and fungal infections, including respiratory tract infections in COPD patients, ventilator-associated pneumonia (VAP), and fungal pneumonia.

"Taken together, our data suggest that Mul-1867 is a promising novel antimicrobial agent that has potent broad-spectrum antibacterial activity against clinically important microorganisms," said Dr. Sushant Kumar, a member of TGV's advisory board. "TGV-Inhalonix has completed comprehensive preclinical and pilot clinical studies of Mul-1867 in Europe, showing good efficacy and safety profile in cystic fibrosis patients. Regarding development in the US, the company plans to conduct Investigational New Drug studies (IND) studies with an IND filing expected in 2018."

Mul-1867 data have been published in several scientific journals and were presented at major microbiology and infectious disease conferences including ASM-2015 and ICAAC-2015.

TGV-Inhalonix is a New York-based Research & Development pharmaceutical company that provides a broad range of innovative products that are developed, manufactured and marketed worldwide by TGV-Laboratories Group of Companies. The research of the TGV-Laboratories Group of Companies is focused on identifying new causes for diseases, as well as blueprinting and creating small molecules and recombinant proteins.

For more information about Victor and George Tetz and TGV-Inhalonix, please contact Max Smetannikov, MVG at 917 310 3396, Email, or Jeri Clausing at 505-221-3108, Email.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/tgv-inhalonix-receives-orphan-drug-status-for-its-novel-antibiotic-to-treat-resistant-infections-in-cystic-fibrosis-300250196.html


'/>"/>
SOURCE TGV-Inhalonix
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. Oramed Receives Patent Term Adjustment Extending the Term of Its U.S. Patent
2. Raymond Sanchez Receives ISCDD Leadership Award at ISCDD 2016 Annual Meeting
3. Edwards Lifesciences Receives Approval For SAPIEN 3 Valve In Japan
4. Arcturus Therapeutics Receives Intent to Grant Notice from the European Patent Office for their Unlocked Nucleomonomer Agent (UNA) Technology
5. CardiacAssist Receives FDA 510(k) Clearance For Its TandemLung Oxygenator
6. Mass. Start-up Interscope Receives European Regulatory Approval, Secures Five U.S. Patents for Medical Devices Innovation
7. Alexza Pharmaceuticals Receives Positive Nasdaq Listing Determination
8. Katama Pharmaceuticals Receives a Notice of Allowance of a Composition of Matter Patent For Tolperisone
9. BD Receives FDA Approval for New Automated Cervical Cancer Screening System
10. Corvia Medical Receives IDE Approval For REDUCE LAP-HF I Clinical Study & Announces Agreement With Strategic Partner For Exclusive Option To Purchase Company
11. Edwards SAPIEN XT Valve Receives FDA Approval For Pulmonic Procedures
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2019)... ... April 17, 2019 , ... Knight Security’s patented KnightSentry technology ... Solution tool by Security Today magazine in its annual The Govies Government Security ... in this contest recognizing outstanding government security products. , Knight’s innovative KnightSentry platform ...
(Date:4/17/2019)... ... April 17, 2019 , ... With the US ... Strategies to Expedite Development of Oncology Drugs and Biologics’ – it ... Through years of experience helping sponsors manage complex oncology trials, endpoint ...
(Date:4/17/2019)... ... April 17, 2019 , ... Women’s Excellence in Obstetrics and Gynecology now offers ... concern, you want to be seen by a provider. We believe in getting ... normal routine as soon as possible.” Dr. Jonathan Zaidan, MD, FACOG, President of Women’s ...
Breaking Medicine Technology:
(Date:4/19/2019)... ... , ... It's time to try a better alternative. Why use ... the matter before those pesky dandruff flakes reach your scalp’s surface, making your life ... before it attacks you. New Don’t Flake Me Out Dandruff & Itchy ...
(Date:4/19/2019)... ... April 18, 2019 , ... Edens Garden launches 7 ... deodorants combine the power of 100% pure essential oils and non-toxic ingredients to keep ... only is Edens Garden’s latest product release all-natural but baking soda- and aluminum-free, making ...
(Date:4/19/2019)... ... 19, 2019 , ... The Patient Advocacy Community of The ... Network-CVPH, Plattsburgh, NY with the 2019 Ruth Ravich Patient Advocacy Award in recognition ... patient advocates. Doyle was honored with the award at The Beryl Institute’s annual ...
(Date:4/18/2019)... ... April 18, 2019 , ... ... ability to deliver targeted radiation to cancer cells while sparing surrounding healthy tissue. ... research platforms. Engineered from the ground up for high reliability and ease of ...
(Date:4/18/2019)... ... April 18, 2019 , ... ... energy, concentration, memory, relaxation and restful sleep to support a healthy mind and ... provide mental clarity, focus and vitality. , The portfolio includes a total of ...
Breaking Medicine News(10 mins):